Novel Theranostic Approaches Targeting CCR4-Receptor, Current Status and Translational Prospectives: A Systematic Review

Background: With the high mortality rate of malignant tumors, there is a need to find novel theranostic approaches to provide an early diagnosis and targeted therapy. The chemokine receptor 4 (CCR4) is highly expressed in various tumors and plays an important role in tumor pathogenesis. This systematic review aims to provide a complete overview on clinical and preclinical applications of the CCR4 receptor as a target for theranostics, using a systematic approach to classify and assemble published studies performed on humans and animals, sorted by field of application and specific tumor. Methods: A systematic literature search of articles suiting the inclusion criteria was conducted on Pubmed, Scopus, Central, and Web of Science databases, including papers published from January 2006 to November 2022. Eligible studies had to be performed on humans and/or in vivo/in vitro studying CCR4 expression in tumors. The methodological quality was assessed through the Critical Appraisal Skills Programme (CASP) assessing only the studies performed on humans. Results: A total of 17 articles were screened. The articles were assessed for eligibility with the exclusion of 4 articles. Ultimately, 13 articles were selected for the qualitative analysis, and six articles were selected for the critical appraisal skills program. Conclusions: The development of new radionuclides and radiopharmaceuticals targeting CCR4 show promising results in the theranostics of CCR4 sensible tumors. Although to widen its use in clinical practice, further translation of preclinical to clinical data is needed.

[1]  T. Noda,et al.  Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma , 2022, Haematologica.

[2]  Chang Xu,et al.  A targeting delivery system for effective genome editing in leukemia cells to reverse malignancy. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[3]  M. Sugaya.  Clinical Guidelines and New Molecular Targets for Cutaneous Lymphomas , 2021, International journal of molecular sciences.

[4]  M. Pomper,et al.  Theranostics in Oncology—Thriving, Now More than Ever , 2021, Diagnostics.

[5]  J. R. Lane,et al.  Systematic Assessment of Chemokine Signaling at Chemokine Receptors CCR4, CCR7 and CCR10 , 2021, International journal of molecular sciences.

[6]  K. Überla,et al.  Upregulation of CCR4 in activated CD8+ T cells indicates enhanced lung homing in patients with severe acute SARS‐CoV‐2 infection , 2021, European journal of immunology.

[7]  O. Schillaci,et al.  Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer , 2021, International journal of molecular sciences.

[8]  Qingwei Zhu,et al.  Lactate-induced M2 polarization of tumor-associated macrophages promotes the invasion of pituitary adenoma by secreting CCL17 , 2021, Theranostics.

[9]  C. Nervi,et al.  Aptamer-based technology for radionuclide targeted imaging and therapy: a promising weapon against cancer , 2020, Expert review of medical devices.

[10]  O. Schillaci,et al.  Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors , 2020, International journal of molecular sciences.

[11]  Lunquan Sun,et al.  Radiation-enhanced expression of CCL22 in nasopharyngeal carcinoma is associated with CCR4+ CD8 T cell recruitment. , 2020, International journal of radiation oncology, biology, physics.

[12]  R. Ueda,et al.  CCR4 Expression in Tumor-Infiltrating Regulatory T Cells in Patients with Squamous Cell Carcinoma of the Lung: A Prognostic Factor for Relapse and Survival , 2019, Cancer investigation.

[13]  P. Porcu,et al.  The histological prevalence and clinical implications of folliculotropism and syringotropism in mycosis fungoides. , 2019, Chinese clinical oncology.

[14]  Yong-mei Yang,et al.  CCR4 Expression Is Associated With Poor Prognosis in Patients With Early Stage (pN0) Oral Tongue Cancer. , 2019, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[15]  Zhen Cheng,et al.  Radionuclide-Labeled Peptides for Imaging and Treatment of CXCR4- Overexpressing Malignant Tumors. , 2019, Current topics in medicinal chemistry.

[16]  S. Bates,et al.  Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma , 2018, American Journal of Clinical Dermatology.

[17]  J. P. Niemeyer‐Corbellini,et al.  Clinical and epidemiological profile of patients with early stage mycosis fungoides* , 2018, Anais brasileiros de dermatologia.

[18]  O. Sabzevari,et al.  Synthesis and evaluation of a 99mTc-labeled chemokine receptor antagonist peptide for imaging of chemokine receptor expressing tumors. , 2017, Nuclear medicine and biology.

[19]  Minmin Shi,et al.  Up-regulation of chemokine receptor CCR4 is associated with Human Hepatocellular Carcinoma malignant behavior , 2017, Scientific Reports.

[20]  Minmin Shi,et al.  Up-regulation of chemokine receptor CCR4 is associated with Human Hepatocellular Carcinoma malignant behavior , 2017, Scientific Reports.

[21]  M. Schwaiger,et al.  [177Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent , 2017, Theranostics.

[22]  Y. Zong,et al.  CCR4 promotes metastasis via ERK/NF-κB/MMP13 pathway and acts downstream of TNF-α in colorectal cancer , 2016, Oncotarget.

[23]  Michael Lassmann,et al.  First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease , 2016, The Journal of Nuclear Medicine.

[24]  J. Jorgensen,et al.  Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. , 2015, Blood.

[25]  Wojciech G. Lesniak,et al.  Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents. , 2015, Molecular pharmaceutics.

[26]  K. Matsushima,et al.  CCR4 and its ligands: from bench to bedside. , 2015, International immunology.

[27]  F. He,et al.  Rictor/mammalian target of rapamycin 2 regulates the development of Notch1 induced murine T-cell acute lymphoblastic leukemia via forkhead box O3. , 2014, Experimental hematology.

[28]  M. Taniwaki,et al.  Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Saji,et al.  A radiogallium-DOTA-based bivalent peptidic ligand targeting a chemokine receptor, CXCR4, for tumor imaging. , 2014, Bioorganic & medicinal chemistry letters.

[30]  Qiang Liu,et al.  Expression of chemokine receptor 4 was associated with poor survival in renal cell carcinoma , 2014, Medical Oncology.

[31]  L. Josephson,et al.  Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression. , 2011, Molecular pharmaceutics.

[32]  Qifeng Yang,et al.  Aberrant expression of chemokine receptor CCR4 in human gastric cancer contributes to tumor‐induced immunosuppression , 2011, Cancer science.

[33]  A. Rudensky,et al.  Altering the distribution of Foxp3+ regulatory T cells results in tissue-specific inflammatory disease , 2007, The Journal of experimental medicine.

[34]  S. Bromley,et al.  CCR4-dependent regulatory T cell function in inflammatory bowel disease , 2007, The Journal of experimental medicine.

[35]  Tomohiko Mori,et al.  Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. , 2006, Nuclear medicine and biology.

[36]  M. Dorf,et al.  Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor , 2005, The Journal of experimental medicine.

[37]  L. Trümper.  From bench to bedside , 2005, Medizinische Klinik.

[38]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[39]  W. Seegers,et al.  Differentiation of Certain Platelet Factors Related to Blood Coagulation , 1955, Circulation research.